New drug trial offers hope for kids with severe bowel disease

NCT ID NCT07158242

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study is testing a drug called afimkibart to see if it can help children aged 2 to 17 who have moderate to severe ulcerative colitis, a painful bowel disease. The main goal is to see how many children achieve remission (where symptoms go away) after 12 weeks and then maintain it for a full year. This is a large, late-stage trial where participants are randomly assigned to receive the drug or a placebo, and neither they nor their doctors know which one they get.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Addenbrooke's Hospital
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Children's Healthcare of Atlanta
RECRUITING

Atlanta, Georgia, 30342, United States
NYU School of Medicine
RECRUITING

New York, New York, 10016, United States
National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan

Conditions

Explore the condition pages connected to this study.

MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS